Understanding how GLP-1 dosing works helps you have smarter conversations with your doctor. Here's what to expect from semaglutide and tirzepatide titration schedules.
Why Dosing Isn't One-Size-Fits-All With GLP-1 Medications
GLP-1 agonists like semaglutide and tirzepatide come in multiple dose strengths, and the dose you start on depends on your starting weight, medical history, and treatment goals. This isn't a situation where one pill fits everyone. Your prescriber considers factors like whether you have type 2 diabetes, how sensitive your digestive system tends to be, and what other medications you're currently taking.
The concept of "titration" means gradually increasing your dose over several weeks. This approach helps your body adjust and significantly reduces side effects that often appear when people jump to higher doses too quickly. Think of it like easing into a cold pool rather than diving in headfirst.
Regulatory approvals differ by country, which means prescribing guidelines vary between FDA, EMA, and ANVISA approvals for the same active ingredient. So if you see dosing recommendations online, make sure they match the version approved where you live. OzemNews often breaks down these regional differences in easy-to-understand posts.
Data from clinical trials shows most participants don't reach the maximum dose during the study period. This suggests many people find an effective dose well below the highest available strength. You don't necessarily need to chase the biggest number on the pen.
How Semaglutide Dosing Works (Ozempic and Wegovy)
Ozempic uses a weekly injection pen with doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. Most people start at 0.25 mg for the first four weeks, regardless of which strength they'll eventually use. This low starting dose isn't meant to produce dramatic results right away. Instead, it gives your system time to adapt.
Wegovy comes in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly doses. The same initial 0.25 mg start is recommended for most adults. Wegovy's additional strength options (1.7 mg and 2.4 mg) reflect its specific approval for chronic weight management, whereas Ozempic carries primary approvals for type 2 diabetes.
The standard titration timeline moves from 0.25 mg to 0.5 mg to 1 mg to 2 mg (for Ozempic) or up to 2.4 mg (for Wegovy). Each step typically lasts approximately four weeks. Your prescriber might extend this timeline if you experience bothersome side effects, or they might move faster if you tolerate the medication exceptionally well.
In clinical trials, participants taking semaglutide 2.4 mg weekly for 68 weeks reported a mean weight loss of around 14.9% of body weight compared to placebo. Those interested in more detailed trial breakdowns and dosing comparisons can find them on the OzemNews website, where we break down clinical data without the jargon.
How Tirzepatide Dosing Works (Mounjaro and Zepbound)
Mounjaro is approved for type 2 diabetes and comes in weekly doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Zepbound carries the same strength options but with an approved indication for weight loss. The naming differs, but the active ingredient and dosing schedule are identical.
The 2.5 mg strength is considered an initial dose only and isn't typically used as a long-term maintenance dose. This surprises many people who assume the starting dose is meant for continued use. In reality, 2.5 mg exists primarily to help your body begin adapting to the medication.
Titration schedules usually follow a 2.5 mg to 5 mg to 7.5 mg pattern, with four-week intervals between increases. Some patients stay on intermediate doses if their response is satisfactory. Not everyone needs to reach the maximum strength to see meaningful results.
In the SURMOUNT-1 trial, participants taking tirzepatide 15 mg weekly achieved a mean weight reduction of approximately 20.9% over 72 weeks. These numbers illustrate why dose escalation matters for outcomes, but they don't mean every patient must reach 15 mg. Your results depend on your individual response.
Who Typically Starts at a Lower Dose and Why
Patients with gastrointestinal sensitivity, a history of nausea, or those who experience strong side effects on other medications often stay at starting doses longer before advancing. Your prescriber might keep you at 0.25 mg for six weeks instead of four if stomach upset is a concern.
Older adults may have dose adjustments recommended based on kidney or liver function. Healthcare providers sometimes slow the titration schedule for this population. Age-related changes in metabolism and medication clearance mean that "standard" timelines don't always apply.
People with type 2 diabetes using insulin or sulfonylureas may need dose adjustments of those medications when starting GLP-1 therapy. This influences how aggressively the GLP-1 dose is increased, since hypoglycemia risk becomes a factor when combining these drug classes.
Anyone who has had pancreatitis should discuss risks thoroughly with their prescriber. GLP-1 medications carry warnings related to this condition in their prescribing information. Your doctor will weigh potential benefits against risks specific to your medical history.
Who Might Start at a Higher Dose or Move Through Titration Faster
Some clinical protocols allow patients with higher baseline BMI to progress more quickly through initial doses if they tolerate the medication well. This doesn't mean skipping doses entirely, but it might mean moving from 0.25 mg to 0.5 mg after two weeks instead of four.
People without diabetes and without significant GI sensitivity sometimes advance to the next dose every two weeks instead of four, depending on their prescriber's judgment. Faster titration works when your body handles the medication without issues.
Patients switching between medications with the same active ingredient, such as moving from Ozempic to Wegovy, may be able to start at a dose closer to their previous maintenance level. Your prescriber won't necessarily make you begin at the very bottom again.
Those who don't experience hunger suppression or mild nausea often assume the medication isn't working. But appetite effects typically develop at higher doses, so slow titration doesn't indicate treatment failure. The early weeks are about building tolerance, not achieving maximum effect.
Dose Adjustments Based on Side Effects and Response
If nausea, vomiting, or diarrhea persist beyond a few days after a dose increase, doctors often recommend returning to the previous dose and holding there longer before attempting another increase. Side effects that hang around aren't something you should simply endure.
"Lost appetite suppression" after a few weeks on the same dose is a common reason people request dose increases. This usually indicates your body has partially adapted and needs the next step to restore the effects you felt initially.
Lab work during treatment may include monitoring of pancreatic enzymes. Elevated lipase or amylase levels can prompt a dose hold or reduction until values normalize. Your prescriber will determine how often this testing is needed based on your situation.
Insurance authorization requirements sometimes dictate dosing steps. Many plans require documented trials of lower doses before approving higher-strength pens. This process can feel frustrating, but it also means your prescriber has a paper trail showing you've given each dose an adequate trial.
What Patients Should Track During Dose Escalation
Recording injection dates, dose strength, and any side effects in a journal or app helps prescribers make informed decisions about timing of increases. The details matter. "I felt sick last week" is less useful than "I felt nauseous for three days after my Tuesday injection."
Weight measurements should be taken consistently, using the same scale, at the same time of day, with similar clothing. Random fluctuations create confusion that makes it hard to tell whether the medication is actually working for you.
Blood sugar logs become essential for patients with diabetes. Both tirzepatide and semaglutide lower glucose and increase hypoglycemia risk when combined with other diabetes medications. Logging readings helps you and your provider catch patterns before they become problems.
Questions about specific dosing scenarios come up frequently in patient communities. Readers who want curated breakdowns of real-world dosing patterns and answers to common questions can find them on OzemNews, where we review what's actually happening in doctor's offices and clinical practice.
FAQ
How long do you stay on each GLP-1 dose before increasing?
Most people stay on each dose for about four weeks. Your prescriber may extend this if you experience significant side effects, or they might shorten the interval if you tolerate the medication very well and your response warrants escalation.
Can you stay on the lowest dose permanently?
Yes, if you're seeing adequate results. Not everyone needs to reach the maximum dose. If your weight loss or glycemic control goals are being met at 0.5 mg or 5 mg, there's no requirement to increase simply because higher strengths exist.
What happens if you miss a dose during titration?
If a dose is missed and more than two days have passed, take your normal dose and then resume your regular weekly schedule. Don't double up to compensate. Contact your prescriber if you miss multiple doses in a row, as you might need to restart from a lower strength.
Do side effects get worse with higher doses?
They can, but not always. Many people find that side effects are most pronounced during the first few weeks on a new dose and then improve as their body adjusts. Others experience consistent mild effects throughout their treatment. Your experience depends on individual factors.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
